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Background. This phase I/II partially blinded, randomized, dose-ranging study assessed the safety and
immunogenicity of a novel human immunodeﬁciency virus type 1 (HIV-1) vaccine candidate consisting of
a recombinant fusion protein (F4) containing 4 HIV-1 clade B antigens (Gag p24, Pol reverse transcriptase, Nef, and
Gag p17) adjuvanted with AS01 in HIV-seronegative volunteers.
Methods. Two doses of the recombinant F4 protein (10, 30, or 90 lg/dose), adjuvanted with AS01 or
reconstituted with water for injection, were administered 1 month apart to 180 healthy volunteers aged 18–40 years.
F4-speciﬁc CD4
1 T cell responses were measured using intracellular cytokine staining after in vitro stimulation by
overlapping peptide pools covering the 4 individual antigens.
Results. Reactogenicity was higher during the 7-day period after each vaccine dose in the adjuvanted than in the
nonadjuvanted groups. In the adjuvanted groups, the overall immune response rate was high after the second
vaccine dose, with highest responder rates seen in the 10-lg F4/AS01 group (100% to 3 HIV-1 antigens and 80% to
all 4 HIV-1 antigens). High and long-lasting CD4
1 T cell frequencies were observed (up to a median value of 1.2%
F4-speciﬁc CD4
1 T cells at day 44), with strongest responses directed against reverse transcriptase. Antigen-speciﬁc
CD4
1 T cells exhibited a polyfunctional phenotype, expressing at least CD40 ligand and interleukin 2, often in
combination with tumor necrosis factor a and/or interferon c. Vaccine-induced CD4
1 T cell responses were
broadly cross-reactive to all 4 antigens derived from HIV-1 clades A and C.
Conclusions. These results support further clinical investigation of this HIV-1 vaccine candidate both in
a prophylactic setting (alone, in conjunction with an envelope-based antigen or in combination with other vaccine
approaches in a heterologous prime-boost regimen) and as a potentially disease-modifying therapeutic vaccine in
HIV-1–infected subjects.
Clinical trials registration. NCT00434512.
Development of a safe and effective prophylactic vaccine
against human immunodeﬁciency virus type 1 (HIV-1)
is a global health priority [1]. Three candidate HIV-1
vaccines have been tested in phase IIb or III trials. An
adenovirus vector-based vaccine and bivalent recombi-
nant gp120 protein vaccines failed to prevent HIV-1
infection [2–4], but a combination of a poxvirus vector
and recombinant gp120 proteins recently demonstrated
modest protection [5]. Although the most desirable goal
ofanHIV-1vaccineremainsthepreventionofinfection,
a disease-modifying vaccine inducing strong T cell–
mediated immune responses remains a valuable alter-
native.
The role of CD8
1 T cell responses in controlling
persistent virus infections is well established [6–9]. Vi-
rus-speciﬁc CD4
1 T cells also play a central role in the
immune control of many viral infections, including
HIV-1 [10]. CD4
1 T cells are required for the induction
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1 T cells [11–14], and the
presence of polyfunctional and proliferation-competent HIV-1–
speciﬁc CD4
1 T cells in HIV-1–infected patients is associated
with long-term nonprogression (LTNP) [15–17]. Loss of HIV-
1–speciﬁc CD8
1 T cell proliferation after acute HIV-1 infection
can be restored by vaccine-induced HIV-1–speciﬁc interleukin
(IL) 2–producing CD4
1 T cells in vitro and in vivo [18].
A previous HIV-1 vaccine candidate comprising gp120 and
a NefTat fusion protein formulated in proprietary
immunostimulatory Adjuvant Systems elicited strong CD4
1
T cell responses in healthy HIV-seronegative adults [19, 20] and
in HIV-1–infected subjects receiving antiretroviral therapy [21].
Based on these ﬁndings and promising results with malaria
[22–24] and recombinant hepatitis B virus [25] antigens,
AS01—a liposome-based Adjuvant System containing 3-O-
desacyl-4’-monophosphoryl lipid A (MPL) and QS21—was
chosen for further investigation due to its propensity to induce
as t r o n g e rC D 4
1 T cell response [20, 25, 26].
Because vaccine-induced CD4
1 T cell responses need to
cover the broadest possible spectrum of circulating HIV-1
strains, an HIV-1 vaccine should contain as many CD4
1 T cell
epitopes as possible from different viral proteins [27]. The
viral antigens containing the highest number of conserved
T cell epitopes are Gag, Pol, and Nef [28]. Given their role in
HIV-1 pathogenesis and as targets for CD8
1 T cell responses
[29, 30], p17 and p24 encoded by gag, reverse transcriptase
(RT) encoded by pol, and the regulatory protein Nef have
beenincluded asasingle fusionprotein (F4)in anovelvaccine
formulation. This study evaluated the safety and immuno-
genicity of the F4 protein antigen adjuvanted with AS01 in
healthy HIV-seronegative volunteers.
MATERIALS AND METHODS
Study Vaccine
The HIV-1 vaccine candidate contained 10, 30, or 90 lgo fF 4
recombinant protein per dose as an active ingredient,
adjuvanted with AS01 or reconstituted with water for injection
(WFI). F4 is a recombinant fusion protein expressed in
Escherichia coli and comprising 4 HIV-1 clade B antigens: p24
(BH10), RT (HXB2), Nef (Bru-Lai), and p17 (BH10). The
vaccine antigen was prepared as a lyophilized pellet containing
F4 in sucrose, ethylenediaminetetraacetic acid, arginine, poly-
sorbate 80, and sodium sulﬁte in phosphate buffer. AS01 is
a liposome-based Adjuvant System containing 50 lgo fM P L
and 50 lg of QS21. The freeze-dried fraction containing the F4
antigen and the liquid fraction consisting of AS01 or WFI, both
presented in a single-dose 3-mL glass vial, were reconstituted by
an unblinded vaccinator, and .5 mL of the reconstituted vaccine
solution was injected into the deltoid muscle of the subject’s
nondominant arm.
Study Design and Participants
This was a phase I/II, single-center, partially blinded, parallel-
group study with a dose-escalating, staggered design
(NCT00434512). The study was approved by the local
independent ethics committee and conducted in accordance
with the Declaration of Helsinki and Good Clinical Practice
guidelines, and all subjects provided written informed consent.
Participants were healthy male and female adults, aged 18–
40years;atlowriskofHIV infection;seronegative forantibodies
against hepatitis B core antigen, hepatitis C virus, HIV-1 and
HIV-2 and negative for hepatitis B surface antigen and HIV p24
antigen in screening serum samples obtained 8 weeks before
vaccination (all tests from Abbott AxSYM). Standard eligibility
criteria were used for enrollment, as detailed in the Clinical-
Trials.gov registry.
Subjects were randomized (5:1) to receive either AS01 (n 5
50) or WFI (n 5 10) for each F4 dose (10, 30, or 90 lg). The
observers were blinded for adjuvantation but not for antigen
content. Each subject received 2 vaccine doses 1 month apart.
Bloodsampleswereobtainedbeforevaccination(day0),2weeks
(day 44) and 1 month (day 60) after the second vaccine dose,
and at months 6 (day 180) and 12 (day 360). All laboratory
assays were performed with blinding.
Safety
Solicited local (injection site pain, redness, swelling) and general
symptoms (fever, fatigue, headache, sweating, myalgia, gastro-
intestinal symptoms) were recorded on diary cards for 7 days
after each vaccination. Symptom severity was graded on a scale
of 1–3, with grade 3 symptoms deﬁned as redness or
swelling .50 mm, fever .39.0C, and any other symptom
preventing normal daily activities. Unsolicited symptoms were
recorded for 30 days after each vaccination. Serious adverse
events were recorded throughout the study.
T Cell Responses
T cell responses were evaluated by intracellular cytokine staining
after in vitro stimulation with p17, p24, RT, and Nef peptide
pools to assess the expression of IL-2, interferon (IFN) c,t u m o r
necrosis factor (TNF) a, and CD40-ligand (CD40L) with an
adaptation of a previously described method [31], using
peripheral blood mononuclear cells (PBMCs) isolated from
venous blood. In brief, thawed PBMCs were stimulated in vitro
with pools of 15-mer peptides overlapping by 11 amino acids
(Eurogentec) covering the sequences of clade B p17, p24, RT, or
Nef matched antigens or medium only in the presence of anti-
CD28 and anti-CD49d antibodies. After 2 hours at 37C, bre-
feldinAwasaddedtoinhibitsignalmoleculesecretionduringan
additional overnight incubation. Cells were harvested, stained
for surface markers (CD4 and CD8), ﬁxed, permeabilized,
and stained with labeled antibodies to IL-2, IFN-c,T N F - a,a n d
CD40L (all reagents, BD Biosciences). Flow cytometric analysis
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Diva Version 6.1.1 (BD Biosciences) or FlowJo Version 8.8.2
(Tree Star) software.
To assess cross-reactivity of vaccine-induced CD4
1 Tc e l l s
with non–clade B HIV-1 antigens, PBMCs collected at days
0 and 44 were analyzed for expression of CD40L and in-
tracellular production of IL-2, IFN-c, and TNF-a, using peptide
pools from clade A (p17 and p24 from TZA173 [Tanzania]; RT
and Nef from KE MSA4070 [Kenya]) and C (ZM651) HIV-1
strains. Clade B antigens were included in the same assay as
controls. This exploratory analysis was performed only on
samples from subjects in the 10-lg F4/AS01 group. Amino acid
alignment analysis was performed using Clustal W2 (Lasergene)
and Jalview Version 2 [32] software. A subject was considered
ar e s p o n d e ri f>.03% antigen-speciﬁc CD4
1 T cells were ob-
served after background subtraction. This cutoff was selected
based on the maximum value of all 95th percentiles for the
percentage of antigen-speciﬁc CD4
1 T cells expressing >2
markers before vaccination.
Humoral Immune Response
Immunoglobulin G (IgG) antibody responses to F4, p17, p24,
RT, and Nef were analyzed by using standard in-house enzyme-
linked immunosorbent assays. Antibody concentrations were
calculatedby comparingthedose-range curve from the analyzed
sample with that of an in-house reference sample. All assays
included negative and positive internal controls. The cutoff for
seropositivity was >187 mEU/mL for p17, >119 mEU/mL for
p24, >125 mEU/mL for RT, >232 mEU/mL for Nef, and >42
mEU/mL for F4.
Statistical Analysis
Analysis of safety was performed on the total vaccinated cohort.
The number and percentage of subjects reporting solicited and/
or unsolicited local and general symptoms were calculated with
exact 95% conﬁdence intervals (CIs).
Analysis of immunogenicity was performed on according-to-
protocol cohorts at months 2 and 12. The frequency of CD4
1 T
cells expressing IL-2 and >1 other marker and the percentage of
responders after in vitro stimulation to each individual antigen
and to at least 1, 2, 3, and all 4 antigens were determined at each
time point. The F4-speciﬁc CD4
1 T cell response was estimated
from the sum of the speciﬁc CD4
1 T cell frequencies in response
to each individual antigen. In the adjuvanted groups, F4-speciﬁc
CD4
1 T cell frequencies 2 weeks after the second vaccination
were compared between doses by 1-way analysis of variance
using the log10 frequencies, with dose (10, 30, and 90 lg)
included as a ﬁxed effect, followed by a Tukey adjustment.
Statistical comparisons between groups were not performed at
any other time.
Seropositivity rates and geometric mean antibody concen-
trations (GMCs) for F4 and each individual antigen were cal-
culated with 95% CIs, using the exact method for binomial
variables for seropositivity rates and the antilogs of the 95% CIs
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Figure 1. CONSORT flow diagram. ATP, according to protocol.
524 d CID 2011:52 (15 February) d HIV/AIDSof the mean log10-transformed antibody concentrations
for GMCs. Antibody concentrations below the assay cutoff
were given an arbitrary value of half the cutoff for the GMC
calculation.
RESULTS
Demographics
The mean (standard deviation) age of study participants was
22.3 (4.62) years, 63.3% were female, and 96.7% were white. No
differences in baseline demographics were observed between
groups. All 180 subjects received both vaccine doses, and 176
completed the study. The according-to-protocol cohort for
analysis of immunogenicity comprised 152 subjects (84.4%) at
month 2 and 150 (83.3%) at month 12 (Figure 1).
Safety
Reactogenicity was higher during the 7-day period after each
vaccine dose in the F4/AS01 groups than in the F4/WFI groups.
The incidence of local and general symptoms tended to be
higher in the F4/AS01 groups after the second vaccine dose
(Figure 2). Pain was the most common solicited local symptom,
reported after 94.0%–98.0% of doses in the F4/AS01 groups and
after 0%–40.0% of doses in the F4/WFI groups (grade 3 severity
after 2.0%–12.2% of doses in the F4/AS01 groups). Fatigue was
the most common solicited general symptom, reported after
Figure 2. Incidence of solicited local and general symptoms (any and grade 3 severity) during the 7-day period after each vaccine dose. Solicited local
symptoms (injection site pain, redness, swelling) and general symptoms (fatigue, fever, gastrointestinal [eg, nausea, vomiting, diarrhea, and abdominal
pain], headache, myalgia and sweating) symptoms were recorded on diary cards for 7 days after each vaccine dose. Symptom severity was graded on
a scale of 1–3, with grade 3 symptoms defined as redness or swelling .50 mm in diameter, fever .39.0C, and any other symptom preventing normal
daily activities.
HIV/AIDS d CID 2011:52 (15 February) d 52554.0%–89.8% and 20.0%–50.0% of doses in the F4/AS01 and
F4/WFI groups, respectively (grade 3 severity after 0–22.4% of
doses in the F4/AS01 groups). No grade 3 fever was reported
after the ﬁrst vaccine doses in the F4/AS01 groups. Grade 3 fever
was reported after 14.0%–22.4% of second vaccine doses in the
F4/AS01 groups. No solicited local or general grade 3 symptoms
were reported in the F4/WFI groups. No differences in
reactogenicity were observed between the antigen dose levels in
the F4/AS01 groups.
During the 30-day postvaccination period, 60.0%–84.0% of
subjects in the F4/AS01 groups reported unsolicited symptoms,
compared with 50.0%–70.0% in the F4/WFI groups. In the F4/
AS01 groups, unsolicited symptoms (mainly chills and injection
site reactions) were considered causally related to vaccination in
30.0%–44.0% of subjects and were of grade 3 severity in
<10.0%. All related symptoms were transient and resolved
without sequelae, generally within 2–3 days. Six serious adverse
events were reported in the F4/AS01 groups, all considered
unrelated to vaccination. No subjects died during the study
period, and no subject withdrew because of adverse events.
CD4
1 T Cell Responses against Homologous Antigens
In all nonadjuvanted groups, the frequency of antigen-speciﬁc
CD4
1 T cells expressing >2 immune markers including IL-2
was below or close to the assay cutoff (data not shown). Very
high responder rates were observed in all F4/AS01 groups 2
weeks after the second vaccine dose (day 44) (Table 1). The
percentage of responders was highest in the 10-lgF 4 / A S 0 1
group, with all subjects responding to >3 antigens and 80.4% to
all4 antigensatthistime.Responsesinthe 10-lg F4/AS01group
were broad and directed against all vaccine antigens, with
highest response rates to the RT antigen. Vaccine-induced
CD4
1 T cellresponses were long-lived, with 97.7%ofsubjectsin
the 10-lgF4/AS01groupstillrespondingto2antigens,84.1%to
3 antigens, and 59.1% to 4 antigens at month 12 (day 360). The
magnitude of response for the F4 fusion protein was signiﬁ-
cantly greater in the 10-lg F4/AS01 group (P , .0001 at day 44
vs both 30 and 90 lg). The response to the F4 fusion protein
induced in the 10-lg F4/AS01 group was still observable at
month 12 (Figure 3). In this group, the median frequency of
F4-speciﬁc CD4
1 T cells producing IL-2 and >1 other marker
peaked at almost 1.2% on day 44 and was maintained at .5% at
month 12.
Vaccine-induced CD4
1 T cells exhibited a polyfunctional
phenotype (Figure 4a). The majority of F4-speciﬁc CD40L
1
CD4
1 T cells produced IL-2 alone or in combination with TNF-
a and/or IFN-c. Approximately 50% of F4-speciﬁc CD40L
1
CD4
1 T cells secreted >2 cytokines, and this cytokine coex-
pression proﬁle was maintained until month 12 (Figure 4b). A
similar proﬁle was observed for all individual antigens (data not
shown).
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526 d CID 2011:52 (15 February) d HIV/AIDSFigure 3. Percentage of CD4
1 Tcells expressing interleukin (IL) 2 and >1 other marker in response to the F4 fusion protein. F4-specific CD4
1 T cell
response was estimated from the sum of the specific CD4
1 T cell frequencies in response to each individual antigen. Results were expressed as the
percentage of the total CD4
1 Tcells expressing IL-2 and >1 other marker (interferon c, tumor necrosis factor a, or CD40 ligand). *P ,.0001 at day 44 for
10 lg versus both 30 and 90 lg groups; statistical comparisons between groups were not performed at any other time. WFI, water for injection.
Figure 4. A, Cytokine coexpression profile of F4-specific CD4
1CD40L
1 Tcells in the 10-lg F4/AS01 group at 2 weeks after the second dose (day 44). B,
Pie charts for all time points in the 10-lg F4/AS01 group. F4-specific CD4
1 T cell response was estimated from the sum of the specific CD4
1 T cell
frequencies in response to each individual antigen. Results were expressed as the percentage of the total CD4
1CD40L
1 T cells expressing 1, 2, or 3
cytokines (interleukin [IL] 2, tumor necrosis factor [TNF] a, or interferon [IFN] c). Pie charts represent percentages as proportions. Values at day 0 were
below or close to the assay cutoff (data not shown).
HIV/AIDS d CID 2011:52 (15 February) d 527CD4
1 T Cell Responses against Heterologous Antigens
Inthe10-lgF4/AS01group,HIV-speciﬁcCD4
1Tce llre sp on s es
at day 0 were below or close to the assay cutoff for all antigens
across all clades (data not shown). Broadly cross-reactive CD4
1
T cell responses to p17, p24, RT, and Nef peptide pools of clade
A and C were seen at day 44 (Figure 5). The magnitude of the
HIV-speciﬁc CD4
1 T cell response against clade A and C
peptides was about half that observed with corresponding clade
B peptides across all antigens. Alignment analysis revealed
74%–93% identity between F4 antigens from clade B and the
other clades (Table 2). All subjects mounted a response to RT
and p24 from clades A and C in line with the high response rates
to the corresponding homologous clade B antigens.
CD8
1 T Cell Responses
Vaccine-inducedCD8
1 T cells werenot detectedbyintracellular
cytokine staining (data not shown).
Humoral Immune Responses
HighimmunoglobulinG antibodyconcentrations againstthe F4
fusion protein were seen in the AS01 groups (Figure 6). All
subjects seroconverted to F4 in the adjuvanted groups, with
similar IgG concentrations for all dose levels that persisted
until month 12. IgG antibodies were elicited against all in-
dividual antigens (data not shown). Very low humoral immune
responses were induced in the nonadjuvanted groups.
DISCUSSION
Although the most desirable goal of an HIV vaccine remains the
induction of a protective immune response that prevents in-
fection and disease, a vaccine that elicits polyfunctional CD4
1 T
cell responses may have disease-modifying potential. Vaccine-
induced polyfunctional CD4
1 T cell responses may contribute
to the maintenance of a functional antiviral immune response,
preventing progressive CD4
1 T cell count decline, reducing or
eliminatingviralreservoirs,inducinglong-termmemory,and/or
Figure 5. Cross-clade reactivity of CD4
1 T cell responses at 2 weeks
after the second dose (day 44) in the 10-lg F4/AS01 group among
responders. Peripheral blood mononuclear cells collected at days 0 and 44
from subjects in the 10-lg F4/AS01 group were analyzed by intracellular
cytokine staining for the expression of CD40 ligand (CD40L) and production
of interleukin (IL) 2, interferon (IFN) c, and tumor necrosis factor (TNF) a,
using peptide pools from clades B, A (p17 and p24 from Tanzania, reverse
transcriptase [RT] and Nef from Kenya), and C (ZM651) human
immunodeficiency virus type 1 (HIV-1) strains. Results were expressed as
the percentage of the total CD4
1 T cells expressing IL-2 and >1o t h e r
marker (IFN-c,T N F - a, or CD40L). Values at day 0 were below or close to
the assay cutoff against each antigen for all clades (data not shown).
Table 2. Cross-Reactivity of CD4
1 T Cell Responses
a
Antigen
HIV-1
Clade
Subjects,
No.
b
Responders
(95% CI),
c %
CD4
1 T Cells Expressing
IL-2 and >1 Other Marker
d
Amino Acid Identity with
Vaccine Antigen, %
p24 B 48 100 (92.6–100) .26 100
A 48 100 (92.6–100) .15 87.1
C 48 100 (92.6–100) .18 92.7
RT B 48 100 (92.6–100) .50 100
A 48 100 (92.6–100) .30 89.8
C 48 100 (92.6–100) .28 92.5
Nef B 46 95.8 (85.7–99.5) .14 100
A 23 47.9 (33.3–62.8) .08 77.7
C 21 43.8 (29.5–58.8) .07 81.1
p17 B 41 85.4 (72.2–93.9) .16 100
A 28 58.3 (43.2–72.4) .07 78.8
C 37 77.1 (62.7–88.0) .08 74.2
a Data include the percentage of responders at 2 weeks after the second dose (day 44) in the 10-lg F4/AS01 group. Peripheral blood mononuclear cells collected
at days 0 and 44 were analyzed by intracellular cytokine staining for the expression of CD40 ligand (CD40L) and the production of interleukin (IL) 2, interferon (IFN) c,
and tumor necrosis factor (TNF) a, using peptide pools from clades B, A (p17 and p24 from Tanzania, reverse transcriptase and Nef from Kenya), and C (ZM651)
human immunodeﬁciency virus type 1 (HIV-1) strains. Results were expressed as the percentage of the total CD4+ T cells expressing IL-2 and at least one other
marker (IFN-y, TNF-a, or CD40L). A subject was considered a responder if the antigen-speciﬁc CD4
1 response was >.03%, the cutoff value.
b Subjects with available results.
c CI, conﬁdence interval.
d Among responders, the median percentage of CD4
1 T cells expressing IL-2 and >1 other marker (IFN-c, TNF-a, or CD40L).
528 d CID 2011:52 (15 February) d HIV/AIDSconferring LTNP status on infected individuals. We recently
assessed the safety and immunogenicity of a gp120/NefTat HIV-
1 vaccine candidate formulated with 1 of 3 different Adjuvant
Systems in healthy HIV-negative volunteers [20]. Strong, per-
sistent, and broadly reactive CD4
1 T cell responses were ob-
served in all vaccine groups but were most pronounced with
AS01.
This study assessed the safety and immunogenicity of
a novel candidate HIV-1 vaccine consisting of the fusion
protein F4 adjuvanted with AS01 in healthy HIV-seronegative
volunteers. The F4/AS01 vaccine had an acceptable safety
proﬁle, consistent with clinical experience with AS01 in
combination with the gp120/NefTat HIV-1 vaccine candidate
[20], recombinant hepatitis B surface antigen [25],
Plasmodium falciparum RTS,S [33], and Mycobacterium tuber-
culosis antigens [34]. The F4/AS01 vaccine elicited a high fre-
quency of F4-speciﬁc polyfunctional CD4
1 T cells that persisted
until month 12. The overall rate of responders was high in all
adjuvanted vaccine groups, with responses elicited against all
vaccine antigens. However, the most potent CD4
1 Tc e l lr e -
sponses were observed in the lowest antigen dose group (10 lg
F4/AS01). Although all subjects who received the F4/AS01 vac-
cine candidate seroconverted to the F4 antigen, no signiﬁcant
differences in antibody responses were seen between the 3 dose
groups. This might indicate important differences in the in-
duction of T versus B cell responses by the candidate vaccine. A
possible explanationfor this phenomenon wouldbe an inﬂuence
of the ratio of adjuvant to antigen dose, a hypothesis meriting
further exploration in future studies.
Vaccine-induced CD4
1 T cells expressed CD40L and pro-
duced IL-2 alone or in combination with TNF-a and/or IFN-c.
This is an important and promising observation, because anti-
viral CD4
1 T cells producing multiple cytokines are considered
functionally superior to those producing single cytokines [35],
and their association with LTNP in HIV-1 infection is well
established [15, 16]. Virus-speciﬁc polyfunctional CD4
1 Tc e l l s
have also been shown to be important for protective immunity
in vaccinated monkeys after simian immunodeﬁciency virus
challenge [36].
HIV-1–speciﬁc CD8
1 T cell responses were not detected with
this vaccine. However, the vigorous CD4
1 T cell responses in-
duced may be able to provide the necessary help to CD8
1 Tc e l l s
induced by other vaccine strategies, such as live vectors when
combined in a prime-boost regimen [37].
An important consideration in HIV-1 vaccine development is
the diversity of the HIV-1 virus worldwide, necessitating the
induction of a broadly cross-reactive immune response [38].
The F4/AS01vaccine, comprisingclade B antigens only, was able
to elicit broadly cross-reactive CD4
1 T cell responses to all 4
antigens derived from clades A and C.
Although these results are encouraging, a potential drawback
of a CD4
1 T cell inducing vaccine is the fact that HIV-1 pref-
erentially infects activated CD4
1 T cells, in particular HIV-1–
speciﬁc CD4
1 T cells [39]. Becauseany HIV-1 vaccinecandidate
will eventually depend on some degree of CD4
1 Tc e l li n d u c t i o n
for an effective antiviral immune response, it may be important
to evoke high levels of CD4
1 T cells to tip the balance in favor of
the immune system. It is reassuring that most vaccines are
routinely administered to HIV-infected patients without any
safety concern or clinically signiﬁcant negative effect on disease
progression or viral load, despite their activation or induction of
CD4
1 T cells [40]. A large phase IIb study of a trivalent
Figure 6. Humoral immune response against the F4 fusion protein. Anti-F4 immunoglobulin G (IgG) antibody concentrations were measured by enzyme-
linked immunosorbent assay and expressed as geometric mean concentrations (GMCs in mEU/mL). The assay cutoff for F4 was >42 mEU/mL. WFI, water
for injection
HIV/AIDS d CID 2011:52 (15 February) d 529recombinant adenovirus-based HIV-1 vaccine did not indicate
any correlation between the level of activated CD4
1 T cells and
enhanced susceptibility to HIV-1 infection or an increased virus
load in individuals who became infected during the study [41].
In conclusion, results of this study show the F4/AS01-
adjuvanted HIV-1 vaccine to be immunogenic with an accept-
able safety proﬁle. Strong polyfunctional, broadly reactive and
persistent CD4
1 T cell responses were induced with 2 vaccine
doses containing 10 lg of F4 protein adjuvanted with AS01. The
properties of the immune response suggest that this vaccine
candidate merits further evaluation both in a prophylactic set-
ting (alone, in conjunction with an envelope-based antigen, or
in combination with other vaccine approaches in a heterologous
prime-boost regimen) and as a potentially disease-modifying
therapeutic vaccine in HIV-1–infected subjects; a clinical study
in such subjects has been initiated (NCT00814762).
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